Filing Details

Accession Number:
0000899243-22-028481
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-12 16:15:57
Reporting Period:
2022-08-10
Accepted Time:
2022-08-12 16:15:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1805387 Cerevel Therapeutics Holdings Inc. CERE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1830363 John Renger C/O Cerevel Therapeutics Holdings, Inc.
222 Jacobs Street, Suite 200
Cambridge MA 02141
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-10 29,624 $3.50 32,328 No 4 M Direct
Common Stock Acquisiton 2022-08-10 25,376 $10.28 57,704 No 4 M Direct
Common Stock Disposition 2022-08-10 36,141 $40.19 21,563 No 4 S Direct
Common Stock Disposition 2022-08-10 18,859 $41.10 2,704 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-08-10 29,624 $0.00 29,624 $3.50
Common Stock Stock Option (Right to Buy) Disposition 2022-08-10 25,376 $0.00 25,376 $10.28
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
80,146 2029-04-02 No 4 M Direct
134,915 2029-04-02 No 4 M Direct
Footnotes
  1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
  2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.57 - $40.565. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.57 - $41.415. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.